Literature DB >> 20965579

Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis.

Yann S Mineur1, Marina R Picciotto.   

Abstract

There is a well-established connection between smoking and depression. Depressed individuals are over-represented among smokers, and ex-smokers often experience increased depressive symptoms immediately after stopping smoking. Nicotine in tobacco binds, activates and desensitizes nicotinic acetylcholine receptors (nAChRs), but it is not known whether activation or desensitization is more important for the effects of nicotine on depressive symptoms. Here we review, based on clinical and preclinical studies of nicotinic drugs, the hypothesis that blockade (rather than activation) of neuronal nAChRs might be important for the effects of nicotinic agents on depressive symptoms. The endogenous neurotransmitter for nAChRs is acetylcholine, and the effects of nicotine on depression-like behaviors support the idea that dysregulation of the cholinergic system might contribute to the etiology of major depressive disorder. Thus, pharmacological agents that limit acetylcholine signaling through neuronal nAChRs might be promising for the development of novel antidepressant medications.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965579      PMCID: PMC2991594          DOI: 10.1016/j.tips.2010.09.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  77 in total

1.  Cigarette smoking and suicide: a prospective study of 300,000 male active-duty Army soldiers.

Authors:  M Miller; D Hemenway; N S Bell; M M Yore; P J Amoroso
Journal:  Am J Epidemiol       Date:  2000-06-01       Impact factor: 4.897

2.  Depressive characteristics of FSL rats: involvement of central nicotinic receptors.

Authors:  Y Tizabi; A H Rezvani1; L T Russell; K Y Tyler; D H Overstreet
Journal:  Pharmacol Biochem Behav       Date:  2000-05       Impact factor: 3.533

3.  Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.

Authors:  Roger E Meyer; Carl Salzman; Eric A Youngstrom; Paula J Clayton; Frederick K Goodwin; J John Mann; Larry D Alphs; Karl Broich; Wayne K Goodman; John F Greden; Herbert Y Meltzer; Sharon-Lise T Normand; Kelly Posner; David Shaffer; Maria A Oquendo; Barbara Stanley; Madhukar H Trivedi; Gustavo Turecki; Charles M Beasley; Annette L Beautrais; Jeffrey A Bridge; Gregory K Brown; Dennis A Revicki; Neal D Ryan; David V Sheehan
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

4.  Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  J Pharmacol Exp Ther       Date:  2010-04-30       Impact factor: 4.030

5.  Dramatic decreases in brain reward function during nicotine withdrawal.

Authors:  M P Epping-Jordan; S S Watkins; G F Koob; A Markou
Journal:  Nature       Date:  1998-05-07       Impact factor: 49.962

Review 6.  Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

Authors:  Henricus G Ruhé; Jochanan Huyser; Jan A Swinkels; Aart H Schene
Journal:  J Clin Psychiatry       Date:  2006-12       Impact factor: 4.384

Review 7.  Smoking cessation leads to reduced stress, but why?

Authors:  A C Parrott
Journal:  Int J Addict       Date:  1995-09

8.  Impaired active avoidance responding in rats selectively bred for increased cholinergic function.

Authors:  D H Overstreet; A H Rezvani; D S Janowsky
Journal:  Physiol Behav       Date:  1990-04

9.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

10.  Comparative behavioral and neurochemical activities of cholinergic antagonists in rats.

Authors:  F P Bymaster; I Heath; J C Hendrix; H E Shannon
Journal:  J Pharmacol Exp Ther       Date:  1993-10       Impact factor: 4.030

View more
  102 in total

1.  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

Authors:  Li-Fang Yu; Werner Tückmantel; J Brek Eaton; Barbara Caldarone; Allison Fedolak; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-01-04       Impact factor: 7.446

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 3.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

4.  Nicotine Addiction and Psychiatric Disorders.

Authors:  Munir Gunes Kutlu; Vinay Parikh; Thomas J Gould
Journal:  Int Rev Neurobiol       Date:  2015-09-19       Impact factor: 3.230

5.  Nicotinic α7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex.

Authors:  Yang Yang; Constantinos D Paspalas; Lu E Jin; Marina R Picciotto; Amy F T Arnsten; Min Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

6.  Synthesis and biological evaluation of novel hybrids of highly potent and selective α4β2-Nicotinic acetylcholine receptor (nAChR) partial agonists.

Authors:  Han-Kun Zhang; J Brek Eaton; Allison Fedolak; Hendra Gunosewoyo; Oluseye K Onajole; Dani Brunner; Ronald J Lukas; Li-Fang Yu; Alan P Kozikowski
Journal:  Eur J Med Chem       Date:  2016-09-09       Impact factor: 6.514

7.  Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests.

Authors:  Arya Haj-Mirzaian; Nastaran Kordjazy; Arvin Haj-Mirzaian; Sattar Ostadhadi; Mehdi Ghasemi; Shayan Amiri; Mehrdad Faizi; AhmadReza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2015-07-15       Impact factor: 4.530

8.  Discovery of highly potent and selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II.

Authors:  Li-Fang Yu; J Brek Eaton; Allison Fedolak; Han-Kun Zhang; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-11-02       Impact factor: 7.446

Review 9.  Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence.

Authors:  Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-03-11       Impact factor: 4.244

10.  Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant.

Authors:  Yang Yuan; Li-Fang Yu; Xi Qiu; Alan P Kozikowski; Richard B van Breemen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-11-23       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.